Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00731861 · ClinicalTrials.gov registry record · Phase 1
Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors
A Phase 1 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00731861 is a Phase 1 study that has completed, run by Indiana University. The registered enrollment target is 28 participants.
The verdict
NCT00731861, a Phase 1 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study will evaluate PTK787, a new oral drug that stops blood vessel development, in combination with Paclitaxel in patients with advanced solid tumors.
Interventions
- DRUG Paclitaxel plus PTK787
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2005-05 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00731861
The ClinicalTrials.gov registry entry for NCT00731861 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel plus PTK787 is the first listed.
NCT00731861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00731861 about?
NCT00731861 is a clinical study titled "Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors". This study will evaluate PTK787, a new oral drug that stops blood vessel development, in combination with Paclitaxel in patients with advanced solid tumors.
What is the current status of trial NCT00731861?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2005-05. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00731861?
The interventions under investigation include: Paclitaxel plus PTK787 (DRUG).
Who is sponsoring clinical trial NCT00731861?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.